Sanofi's prostate cancer drug Jevtana gains FDA approval

06/17/2010 | Wall Street Journal, The

The FDA approved Sanofi-Aventis' chemotherapy drug Jevtana for use in combination with prednisone in patients with advanced prostate cancer. The approval was based on studies that demonstrated a median overall survival of 15.1 months for men who received the combination, compared with 12.7 months for those who received mitoxantrone plus prednisone.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations